A whale with a lot of money to spend has taken a noticeably bullish stance on BridgeBio Pharma.
Looking at options history for BridgeBio Pharma BBIO we detected 11 strange trades.
If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $59,828 and 9, calls, for a total amount of $472,490.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $45.0 for BridgeBio Pharma over the last 3 months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for BridgeBio Pharma's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of BridgeBio Pharma's whale trades within a strike price range from $15.0 to $45.0 in the last 30 days.
BridgeBio Pharma Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| BBIO | CALL | TRADE | BEARISH | 07/21/23 | $17.50 | $165.0K | 4.8K | 113 |
| BBIO | CALL | TRADE | BULLISH | 08/18/23 | $30.00 | $91.8K | 15.1K | 226 |
| BBIO | CALL | TRADE | NEUTRAL | 09/15/23 | $35.00 | $37.4K | 1.5K | 1.1K |
| BBIO | CALL | SWEEP | BULLISH | 01/17/25 | $45.00 | $33.9K | 250 | 50 |
| BBIO | PUT | SWEEP | BULLISH | 09/15/23 | $35.00 | $30.7K | 191 | 95 |
Where Is BridgeBio Pharma Standing Right Now?
- With a volume of 2,121,939, the price of BBIO is down -1.59% at $33.94.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 13 days.
What The Experts Say On BridgeBio Pharma:
- Jefferies downgraded its action to Hold with a price target of $33
- Raymond James has decided to maintain their Outperform rating on BridgeBio Pharma, which currently sits at a price target of $46.
- Goldman Sachs has decided to maintain their Buy rating on BridgeBio Pharma, which currently sits at a price target of $50.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for BridgeBio Pharma, Benzinga Pro gives you real-time options trades alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
